Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.39 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.39 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.39 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | SYNJ2 | O15056 | 3/20 | 0.36 |
| ▸ | TYMP | P19971 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14819156 | 0.91 | LGALS3 (0.50) | POLBLGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| SCHEMBL14819208 | 0.91 | LGALS3 (0.50) | POLBLGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| SCHEMBL5319950 | 0.90 | LMNA (0.43) | LMNAKMT2APOLBALDH1A1MEN1 | |
| SCHEMBL5319948 | 0.90 | LMNA (0.43) | LMNAKMT2APOLBALDH1A1MEN1 | |
| SCHEMBL16018720 | 0.86 | LGALS3 (0.45) | KMT2APOLBLGALS9LGALS1LGALS3 | |
| SCHEMBL7889307 | 0.85 | LMNA (0.44) | LMNAKMT2APOLBLGALS9LGALS1 | |
| SCHEMBL22389307 | 0.83 | KMT2A (0.42) | LMNAKMT2APOLBLGALS9LGALS1 | |
| SCHEMBL19613824 | 0.82 | PTPN1 (0.44) | KMT2APOLBLGALS9LGALS1LGALS3 | |
| SCHEMBL27464799 | 0.82 | PTPN1 (0.47) | KMT2APOLBLGALS9LGALS1LGALS3 | |
| SCHEMBL16392942 | 0.81 | LMNA (0.48) | LMNAKMT2APOLBALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10918732-B2 | Glycoconjugates and methods for their use | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-02-16 | — | — | US | disclosed |
| US-20190343960-A1 | GLYCOCONJUGATES AND METHODS FOR THEIR USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-11-14 | — | — | US | disclosed |
| US-10363319-B2 | Glycoconjugates and methods for their use | THE BOARD OF REGENTS OF THE UNIVERITY OF TEXAS SYSTEM (US) | 2019-07-30 | — | — | US | disclosed |
| US-20170333568-A1 | GLYCOCONJUGATES AND METHODS FOR THEIR USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343960-A1 | GLYCOCONJUGATES AND METHODS FOR THEIR USE | LGALS3, B3GAT3, GALNT3 | LMNA 1760/4885KMT2A 3309/4885POLB 4073/4885 |
| US-10918732-B2 | Glycoconjugates and methods for their use | LGALS3, B3GAT3, GALNT3 | LMNA 1760/4885KMT2A 3309/4885POLB 4073/4885 |
| US-10363319-B2 | Glycoconjugates and methods for their use | B3GAT3, LGALS3, GALNT3 | LMNA 1712/4885KMT2A 3288/4885POLB 3949/4885 |
| US-20170333568-A1 | GLYCOCONJUGATES AND METHODS FOR THEIR USE | B3GAT3, LGALS3, GALNT3 | LMNA 1712/4885KMT2A 3288/4885POLB 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.